NOWOX Oxygen Therapy Monitoring Device

February 26, 2014 updated by: Air Liquide SA

Evaluation of NOWOX: a Medical Device Developed to Record Duration of Oxygen Use and Respiration Rate in Patients Requiring Oxygen Therapy

The purpose of this study is to evaluate the duration of oxygen use recorded by the NOWOX, under usual conditions of daily living, in patients with chronic obstructive respiratory disease requiring oxygen therapy.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Long Term Oxygen Therapy (LTOT) is one of the main non pharmacologic treatments for patients with severe lung disease. This continuous or sub-continuous oxygen supplementation is generally introduced at home in patients who have chronic cardio respiratory failure and severe resting hypoxemia to maintain sufficient blood oxygenation and therefore preserve vital organ function.

LTOT effectiveness has mainly been evaluated and documented in patients with COPD, which also accounts for most of its prescriptions. In these patients, LTOT has been shown to have a beneficial impact on haemodynamics, exercise capacity, lung mechanics and mental state. Its implementation was furthermore associated with reduced yearly hospitalisation days and increased survival Measuring adherence is an extremely important and under-evaluated component of oxygen therapy. NOWOX, medical device has been designed,developed and manufactured to measure adherence to LTOT and additionally to measure patient's respiration rate

Study Type

Interventional

Enrollment (Actual)

10

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Paris, France, 75014
        • Cochin University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male or female patient aged ≥ 18 years and ≤ 75 years,
  • Having a documented diagnosis of moderately severe to severe chronic obstructive respiratory disease
  • Hospitalised or out-patient requiring transient or long term oxygen therapy,
  • Able to be weaned from oxygen for several consecutive minutes (around 30 minutes, SpO2 at rest on room air should not drop < 85%),
  • Able to read
  • Willing and able to complete the requirements of this study including providing his/her signature for the written informed consent.

Exclusion Criteria:

  • Clinically unstable patient,
  • Any contraindication to perform a light cycling exercise, according to the 2003 ATS/ACCP guidelines
  • Tracheostomy,
  • Nasal obstruction or acute rhinitis occurring in the week prior to selection,
  • For female patient:
  • Pregnant,
  • Positive urinary pregnancy test
  • Lactating mother or lack of efficient contraception
  • Clinically significant or uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, autoimmune, neurological or psychiatric disorders which may interfere with the study procedures,
  • Known allergic reactions to medical material compounds used in the study
  • Drug abuse or psychic disorders
  • Legal status which prohibits informed consent,
  • Participation in any interventional clinical trial within 30 days prior to selection.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Allocation: NA
  • Interventional Model: SINGLE_GROUP
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: oxygen therapy
one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Primary performance criterion is the overall estimated duration of oxygen use
Time Frame: 6 hours
6 hours

Secondary Outcome Measures

Outcome Measure
Time Frame
secondary performance criterion: instantaneous respiration rate recorded by the NOWOX
Time Frame: 6 hours
6 hours
secondary performance criterion: patient's satisfaction questionnaire on the NOWOX
Time Frame: 1 hour
1 hour

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Anh-Tuan DINH-XUAN, Professor-MD, Department of Physiology - Cochin University Hospital - FRANCE

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2008

Primary Completion (ACTUAL)

February 1, 2010

Study Completion (ACTUAL)

February 1, 2010

Study Registration Dates

First Submitted

November 28, 2008

First Submitted That Met QC Criteria

November 28, 2008

First Posted (ESTIMATE)

December 1, 2008

Study Record Updates

Last Update Posted (ESTIMATE)

February 27, 2014

Last Update Submitted That Met QC Criteria

February 26, 2014

Last Verified

February 1, 2014

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Obstructive Pulmonary Disease

3
Subscribe